Filter posts

New Report Suggests RDP Does Not Increase Healthcare Expenditures

A new paper by the Geneva Network suggests that increasing the period of regulatory data …

Riding the Bull Market: What’s in Store for Biotech Dealmakers in 2015?

In many ways, 2014 was a record year for biopharma dealmaking, with $355 billion in …

The Next Step: How Companies Build Successful Therapeutic Franchises from the Ground Up

Building a new franchise in a therapeutic from scratch poses a host of challenges, from …

Wednesday Recap of BIO 2015: What the Official Bloggers Have to Say

Everyday our BIO Official Bloggers, writers who are on top of the biotechnology beat, release …

The Future of Health and Medicine in the Digital Era

Dr. Daniel Kraft is a well-known Stanford and Harvard trained physician-scientist and innovator with over …

Expanding the Role of Patients in Drug Development

Working alongside scientists, universities, and biotech companies, patients and patient organizations have the ability to …

BIO 2015 Kicks Off: Patient-Focused Drug Development Key Theme of Day One

The BIO International Convention kicked off in Philadelphia today with a strong emphasis on patient-focused drug …

Prepare and Protect from Biological Threats

Yesterday the Alliance for Biosecurity hosted a panel that outlined the important role played by …

MIT Hacking Medicine Presents Idea Design Studio at #BIO2015

Have you ever wanted to improve your healthcare experience? Have you ever felt like you …

John Lechleiter Forbes Op-Ed: Debunking the Five Big Myths About 'Big Pharma'

This week, Eli Lilly and Company President, Chairman and CEO John Lechleiter refutes five big …